Drug Delivery最新文献

{"title":"Unlocking the potential of mesoporous silica nanoparticles: balancing biomedical applications and safety concerns.","authors":"Yingze Hou, Can Zhu, Zhean Shen, Desheng Cao, Liangyu Wei, Jiyu Yang, Chaoyue Shi, Meiqian Wu, Songyun Zheng, Yan Chen, Xianchun Zhou","doi":"10.1080/10717544.2026.2624186","DOIUrl":"10.1080/10717544.2026.2624186","url":null,"abstract":"<p><p>Mesoporous silica nanoparticles (MSNs) have garnered significant attention across various disciplines, including chemistry, physics, and materials science, owing to their distinctive properties and functionalities. Numerous studies have demonstrated that MSNs possess several advantageous characteristics, such as tunable pore sizes, excellent biocompatibility, and a high specific surface area. These attributes render mesoporous silica nanoparticles promising for diverse applications in medical fields, including in vivo targeting, drug delivery, and disease diagnosis. Nevertheless, recent research has indicated that mesoporous silica may induce cellular and tissue toxicity in humans, necessitating further evaluation of its long-term safety. Additionally, parameters such as the shape, particle size, and surface modification of MSNs require careful control to enhance their biodegradability, regulate the circulation time of nanomaterials within the body, and mitigate the immunogenicity of mesoporous silica, thereby facilitating the clinical translation of mesoporous silica nanoparticles. This article reviews the advancements in research concerning the use of mesoporous silica nanomaterials in targeted therapy, drug delivery, and tissue engineering. This work evaluates the potential applications of mesoporous silica materials in the biomedical sector and delineates future research directions for MSNs by examining and summarizing their biological toxicity and associated risks.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"33 1","pages":"2624186"},"PeriodicalIF":8.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unlocking the \"undruggable\": current landscape and emerging frontiers in lysosomal receptor-mediated protein degradation.","authors":"Yi-Meng Ma, Hou-Fu Xia, Yi-Lei Xiao, Zi-Li Yu","doi":"10.1080/10717544.2026.2636323","DOIUrl":"10.1080/10717544.2026.2636323","url":null,"abstract":"<p><p>Extracellular and membrane-associated proteins are essential in signal transmission, immunological control, and disease pathogenesis; nonetheless, their 'undruggable' characteristics have historically impeded drug discovery. The targeted protein degradation (TPD) technologies provide innovative solutions to address this dilemma. Despite the rapid advancement of techniques such as Proteolysis-targeting chimera (PROTACs) that utilize the Ubiquitin-proteasome system (UPS), their applicability is limited to intracellular proteins. Lysosome-targeting chimeras (LYTACs), utilizing the endocytosis-lysosomal route, facilitate the selective degradation of secreted and transmembrane proteins, thereby considerably broadening the target spectrum of TPD. Since its inception in 2020, the LYTAC platform has consistently progressed, incorporating several Lysosome-targeting receptor (LTR) targeting techniques and innovative delivery vehicles, including aptamers, peptides, and nanoparticles. It has exhibited promise in oncology, neurological conditions, and immune-mediated disorders. Nevertheless, LYTAC encounters several obstacles, such as intricate ligand design, potential immunogenicity, inadequate tissue selectivity, and restricted clinical validation. Platforms and tactics designed to improve degrading efficiency, broaden disease applicability, and facilitate clinical translation signify interesting research avenues in this domain. This paper presents a thorough evaluation of the research advancements and application potential of LYTAC technology, while examining significant limitations and future direction of development.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"33 1","pages":"2636323"},"PeriodicalIF":8.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12943813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147303823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.","authors":"Ryan H Huston, Blake Cox, Chaitenya Verma, Thalia Pacheco-Fernandez, Greta Volpedo, M Junaid Dar, Yulian Mercado, Abigail R Wharton, Max Gessner, Nandu Purayil, Ivana Arsovska, Leah Watkins, Junqi Lu, Jennifer Y Zhang, Andrew Sachan, Roger J Narayan, Abhay R Satoskar","doi":"10.1080/10717544.2026.2665882","DOIUrl":"https://doi.org/10.1080/10717544.2026.2665882","url":null,"abstract":"<p><p>Amphotericin B (AmB) is a potent, accessible, FDA-approved drug against CL with damaging side effects. While newer lipid formulations have less toxicity, limitations include affordability and cold-chain requirements. CL affects mostly impoverished communities, which complicates travel to urban hospitals for treatment. Therefore, an off-clinic drug delivery system is desirable. Microneedles can deliver AmB directly to localized CL lesions, which we hypothesized would limit parasite growth without systemic toxicity. Thus, a three-by-three array of 1 mm tall stainless steel hollow microneedles was evaluated in this study. To test their efficacy, we utilized <i>Leishmania mexicana-</i>infected mice to model American CL. Following 20- and 10-consecutive day microneedle treatments (<i>n</i> = 5/group), the 20-day trials more strongly limited lesion growth by up to 2.8 mm versus a maximum 1.1 mm difference between the drug and placebo groups in the 10-day trial (<i>p</i> = 0.008, <i>p</i> = 0.075, respectively). Also, treatments were associated with reduced parasitic burden weeks after treatment cessation, as assessed by limiting dilution (<i>p</i> = 0.057 for 10-day, <i>p</i> = 0.075 for 20-day; one-tailed Mann‒Whitney <i>U</i> test). No elevation of blood serum creatinine or blood urea nitrogen levels was observed, supporting the hypothesis of lessened kidney toxicity. Additionally, flow cytometry explorations showed differences in IL-17 and IFN-γ positivity, and histological changes were observed in the upper dermis. These promising results represent the first test of hollow microneedles for CL treatment and pave the way for further trials. The adoption of microneedles could reduce CL burden in affected communities because of their ease of use, efficacy, and safety with a pre-approved drug.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"33 1","pages":"2665882"},"PeriodicalIF":8.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction.","authors":"","doi":"10.1080/10717544.2025.2610853","DOIUrl":"10.1080/10717544.2025.2610853","url":null,"abstract":"","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"33 1","pages":"2610853"},"PeriodicalIF":8.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12829409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Introducing personalized patient care in overactive bladder management using the MedRing OAB system for intravaginal oxybutynin administration.","authors":"S I Peltenburg, I Koopmans, O Heerema-Snoep, E S Klaassen, M J Juachon, A Otten, N B Klarenbeek","doi":"10.1080/10717544.2026.2617683","DOIUrl":"10.1080/10717544.2026.2617683","url":null,"abstract":"<p><p>Although numerous drugs have been developed for intravaginal administration, the implementation of personalized intravaginal treatment options is limited. The MedRing overactive bladder (OAB) system is a medical device for intravaginal oxybutynin administration via patient-controlled schedules. The primary aim was to assess the feasibility, tolerability, and safety of intravaginal oxybutynin administration via the MedRing OAB system. Second, the functioning of the MedRing OAB system, user satisfaction and quality of life (QoL) were assessed. Female OAB patients were included to receive the MedRing OAB system. Treatment was divided into three periods with increasing dosing flexibility: 2 mg at three fixed timepoints daily, 2 mg at three patient-defined timepoints daily, and flexible dosing up to 6 mg/day of 1 or 2 mg doses. Feasibility, tolerability, satisfaction, and QoL were assessed via questionnaires, safety via treatment-emergent adverse events (TEAEs), device deficiencies (DDs) and physical examination and functioning via pharmacokinetics and MedRing logs. Thirteen patients were enrolled, of whom three patients discontinued the study prematurely. Most patients reported low user burden, found the system practical and expressed positive opinions. The TEAEs were consistent with known oxybutynin effects and local TEAEs were comparable to other intravaginal devices. Most DDs were synchronization difficulties, which improved after a software update. After 10 minutes, oxybutynin levels were detected in 12 of the 13 patients. This study showed that the MedRing OAB system appears to be a feasible, tolerable and safe alternative intravaginal oxybutynin administration for 28 days in OAB patients, offering a potential alternative to existing treatment options and introducing personalized patient care.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"33 1","pages":"2617683"},"PeriodicalIF":8.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12833890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cryopreservation technology for improving the stability of liposomes and its precise drug monitoring in clinical drug research.","authors":"George Frimpong Boafo, Ibrahim Shaw, Marlene Davis Ekpo, Lei Wang, Yimer Seid Ali, Songwen Tan, Ziyu Zhu, Rongrong Wang, Chuanpin Chen, Hongliang Zheng","doi":"10.1080/10717544.2026.2614101","DOIUrl":"10.1080/10717544.2026.2614101","url":null,"abstract":"<p><p>The instability of liposomes in blood samples during clinical drug research and drug monitoring results in the inability to accurately determine the actual drug concentrations in the body at the time of collection, mainly due to lipid deterioration, particle fusion or aggregation, and phase separation degradation, resulting in payload leakage. To improve drug monitoring accuracy, we developed a cryopreservation strategy in this study by innovatively combining cryoprotective agents (CPAs), such as L-proline, sucrose, and polyvinyl alcohol (PVA), to prevent liposomal leakage and maintain stability for reliable drug monitoring and clinical drug research applications. Doxorubicin liposomes were prepared, and the CPAs were tested at various concentrations and under different freeze‒thaw protocols in biological matrices, with the stability and leakage of the liposomes assessed. Each CPA contributes distinct stabilization mechanisms, with L-proline's osmoprotective ability, sucrose's hydrogen bonding, and PVA's steric hindrance to form a protective barrier. The optimized CPA combination demonstrated superior performance at 85% (v/v) by preserving liposomal integrity, offering the best cryoprotective effect for liposomes in plasma stored at -20 °C, achieving about 90% entrapment efficiency, compared to about 60% in the control group without CPAs. Mechanistic investigations confirmed that CPAs protect liposomes against mechanical stress, prevent membrane disruption, and reduce ice damage by inhibiting recrystallization and adjusting bilayer hydration. These findings offer practical solutions for accurate pharmacokinetic assessments and reliable personalized dosing, safer alternative for liposomal drug research, biobanking, and real-world therapeutic monitoring.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"33 1","pages":"2614101"},"PeriodicalIF":8.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12818334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re-engineering insulin for oral delivery: structural modifications, advanced formulation strategies, and future directions.","authors":"Yilin Zheng, Xiaoyi Fang, Jiangtao Gao","doi":"10.1080/10717544.2026.2624192","DOIUrl":"10.1080/10717544.2026.2624192","url":null,"abstract":"<p><p>Oral insulin delivery represents a transformative approach to diabetes management, offering improved patient compliance and physiological insulin delivery patterns compared to subcutaneous injection. However, multiple gastrointestinal barriers, including enzymatic degradation, mucus entrapment, epithelial impermeability, and first-pass metabolism, have limited oral bioavailability to below 1% for unmodified insulin. This review comprehensively examines contemporary strategies to overcome these barriers. We analyze structural modifications of insulin, including PEGylation, lipidation, cyclization, and glycoengineering, which enhance stability while maintaining biological activity. The analysis extends to sophisticated formulation technologies incorporating nanocarriers (polymer-based, lipid-based, inorganic nanocarriers, and metal organic frameworks), biomimetic systems, and stimuli-responsive mechanisms for protection and delivery. A central focus is on absorption-enhancing strategies, which range from chemical permeation enhancers to precise biological mechanisms like receptor-mediated transcytosis and other active transport pathways. Emerging tools such as microbiome-based carriers and smart devices are also discussed. Despite significant progress in preclinical models, challenges remain in manufacturing scalability, inter-patient variability, long-term safety, and regulatory approval. Future directions emphasize hybrid delivery systems, digital health integration, and personalized formulations. Realizing clinically viable oral insulin requires continued multidisciplinary collaboration addressing biological, technological, and translational barriers to transform diabetes care.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"33 1","pages":"2624192"},"PeriodicalIF":8.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12879506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical delivery of Mir-497 using cationized gelatin/sodium alginate coacervates for diabetic wound healing.","authors":"Eunmi Ban, Youngun Yu, Yeojin Kim, Jeil Lee, Seung-Hoi Koo, Jinyoung Park, Aeri Kim","doi":"10.1080/10717544.2026.2654929","DOIUrl":"https://doi.org/10.1080/10717544.2026.2654929","url":null,"abstract":"<p><p>MicroRNA (miRNA)-based therapeutics are promising for chronic inflammatory diseases, yet their clinical translation is limited by poor stability, inefficient intracellular delivery, and safety concerns. Previously, we reported <i>in vitro</i> anti-inflammatory activity of miR-497 encapsulated in coacervate-based delivery platform composed of cationized gelatin (CG) and sodium alginate (SA). In the present study, we modulated the degree of CG cationization and the CG/SA weight ratio to obtain miR-497-loaded CG/SA (miR-497@CG/SA) coacervates with controlled physicochemical properties. The optimized coacervates exhibited particle sizes of approximately 250-300 nm, positive zeta potentials (+15 to + 35 mV), high transfection efficiency, and minimal cytotoxicity. Compared with binary miR-497@CG complexes, the ternary coacervates showed enhanced stability and markedly improved cellular uptake. Confocal microscopy revealed efficient endocytic internalization followed by endo-lysosomal escape into the cytosol. In high glucose-treated human dermal fibroblasts, miR-497@CG/SA significantly promoted cell migration (~1.7-fold increase) and suppressed pro-inflammatory cytokine expression (<i>TNF-α</i>, <i>IL-6</i>, and <i>IL-1β</i>). In a diabetic mouse wound model, topical application of freeze-dried miR-497@CG/SA coacervate sponges achieved over 80 % wound closure within 6 days, accompanied by marked suppression of inflammatory responses. Collectively, these findings demonstrate that CG/SA coacervates provide a safe, efficient, and scalable platform for miRNA delivery, highlighting their potential as a clinically relevant topical gene therapy for diabetic wound healing.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"33 1","pages":"2654929"},"PeriodicalIF":8.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The colloidal stability of albumin-based drug delivery systems has a profound effect on tumoricidal activity.","authors":"Guojun Xiong, Chengwei Jiang, Andreas G Schätzlein, Ijeoma F Uchegbu","doi":"10.1080/10717544.2026.2614801","DOIUrl":"10.1080/10717544.2026.2614801","url":null,"abstract":"<p><p>Human serum albumin (HSA) has attracted significant attention in drug delivery since the approval of Abraxane in 2005. Abraxane is a nanoparticle albumin-bound paclitaxel (nab-PTX) formulation. Although HSA offers advantages such as prolonged circulation time (half-life ~19 days) and intrinsic hydrophobic pockets, the translation of other HSA-based nanomedicines remains limited. In fact, the significant differences between native and pharmaceutical HSA in protein structure and biological interactions could hinder their translational use in drug delivery. In this study, we demonstrate that pharmaceutical HSA (<i>α</i>-helix = 17%) is structurally denatured compared with native HSA (<i>α</i>-helix = 68%), leading to rapid clearance (<1 h) from the circulation and that drug loading is driven by pharmaceutical HSA's amphiphilicity rather than by its hydrophobic pockets. Here, we revealed that Nab-PTX is composed of protein-coated PTX solid cores. These nanosystems have insufficient surface charge (<i>ζ</i> = -13.7 mV), leading to aggregation, and low colloidal stability, resulting in premature drug release upon dilution (<0.1  mg/mL). To address these shortcomings, we developed HSA-polylactic acid (HSA-PLA) nanoparticles with enhanced negative surface charge (<i>ζ</i> = -27.4 mV) and improved colloidal stability to reduce the premature release of encapsulated PTX upon dilution (<0.01  mg/mL). In tumor models, comparative pharmacokinetics, biodistribution, and efficacy studies demonstrated that HSA-PLA (PTX) nanoparticles reduce premature drug release, resulting in greater tumor exposure (129 ± 3 vs. 90 ± 12 µg·h/g, <i>p</i> < 0.01) and superior antitumor efficacy compared with Abraxane. These improvements further suggest that optimization may require only a simple modification when guided by proper theoretical principles.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"33 1","pages":"2614801"},"PeriodicalIF":8.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12821350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydrogel-Based intraperitoneal drug delivery platforms for peritoneal metastasis: strategies, advances, and prospects.","authors":"Xianyan Chen, Yuanfeng Wei, Xiaorong Chen, Lingnan Zheng, Yaqin Zhao, Jia You, Cheng Yi, Xi Yang","doi":"10.1080/10717544.2025.2576199","DOIUrl":"10.1080/10717544.2025.2576199","url":null,"abstract":"<p><p>Peritoneal metastasis (PM), as a terminal stage of malignant tumors with extremely poor prognosis, remains a clinical challenge. Intraperitoneal (IP) administration enhances local drug concentrations, improving survival outcomes for PM patients. However, rapid drug clearance and uneven distribution limit its therapeutic potential. In recent years, hydrogel-based drug delivery systems have garnered attention due to their excellent biocompatibility, drug loading capacity, and controlled release properties. The use of hydrogel-loaded drugs via IP injection can significantly improve anti-cancer efficacy by increasing the local drug concentration, prolonging the retention time of the drug in the peritoneal cavity, and decreasing systemic toxicity. This review summarizes the pathogenesis and current treatment strategies of PM, emphasizing various drugs (including chemotherapy agents, immunotherapeutics, targeted drugs, radioactive isotopes, and herbal medicines) delivered via hydrogel-based IP administration. Furthermore, it highlights the potential of nanoparticles and microparticle-hydrogel composites to further improve drug delivery, offering new strategies for PM treatment and theoretical basis for clinical rational drug use.</p>","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"33 1","pages":"2576199"},"PeriodicalIF":8.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12720670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145780493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}